Daniel Bednarik Ph.D.

Daniel Bednarik, Ph.D., serves as the Senior Vice President of Molecular Engineering & Protein Design, bringing over three decades of expertise as a translational scientist and executive in the biotechnology sector. His career includes significant roles such as Vice President of the Molecular Engineering Unit at Intrexon Corp, along with senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. Throughout his career, Bednarik has led numerous projects aimed at translating promising technologies into viable product developments, particularly in the areas of cancer and cardiovascular diseases. Notably, he created the largest known cardiovascular transcriptomic gene expression database while at Gene Logic, Inc. His contributions to the field have been recognized with substantial funding, including a $1.7 million DARPA contract awarded in 2006 for developing a novel non-host method for rapid vaccine manufacture. Bednarik also completed a post-doctoral fellowship at the Johns Hopkins University Oncology Center, further solidifying his expertise in molecular engineering and translational medicine.